Liqxaban is an anticoagulant that reduces blood clotting and reduces the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Liqxaban selectively inhibits free & clot bound factor Xa, independent of antithrombin III. Liqxaban also inhibits prothrombinase. These effects prevent the formation of a thrombus. Liqxaban selectively inhibits free & clot bound factor Xa, independent of antithrombin III. Liqxaban also inhibits prothrombinase. These effects prevent the formation of a thrombus. Liqxaban is indicated for reducing the risk of stroke and systemic embolism in patients who have nonvalvular atrial fibrillation, prophylaxis of deep vein thrombosis (DVT) leading to pulmonary embolism (PE) in patients after a hip or knee replacement surgery, and treatment of DVT and PE to reduce the risk of recurrence.

Dosage: In stroke & prevention of NVAF, the dosing is 5 mg BD with or without food. Incase of patient meeting 2-3 criteria of either age greater than 80 years, body weight less than 60kg or creatinine greater than 1.5 mg/dl then the dosage must be reduced to 2.5mg BD.